Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense retinoic acid receptor beta2
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Antisense retinoic acid receptor beta2 refers to a genetic construct, typically an antisense cDNA or oligonucleotide, designed to specifically inhibit the expression of the Retinoic Acid Receptor Beta 2 (RAR-beta2) isoform. RAR-beta2 is a member of the thyroid-steroid hormone receptor superfamily and acts as a ligand-dependent transcription factor that often functions as a tumor suppressor in various cancers, including esophageal and oral squamous cell carcinomas. In research settings, antisense RAR-beta2 is utilized to downregulate the receptor's expression to investigate its biological role, such as its ability to suppress cyclooxygenase-2 (COX-2) expression. By blocking RAR-beta2, researchers can induce COX-2 and promote tumor cell growth, thereby confirming the receptor's role in mediating retinoid-induced growth inhibition and clinical response.
- Other names
- antisense RAR-beta2antisense RAR-beta2 cDNA
02
Targets
RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on antisense retinoic acid receptor beta2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense retinoic acid receptor beta2.